Date: Sunday, November 5, 2017
Session Type: ACR Poster Session A
Session Time: 9:00AM-11:00AM
Background/Purpose: We have found that patients with a variety of rheumatic diseases who have concomitant fibromyalgia more frequently fail therapies for the underlying inflammatory rheumatic disease and osteoarthritis. Based on the 2010 ACR criteria for the diagnosis of fibromyalgia, a screening form was developed at the time of the study for accurate diagnosis. The screening assessment form is filled in by patients. It includes 19 pain areas as well as questions concerning sleep, energy, cognition, headache, abdominal pain, and depression. Adding this fibromyalgia screening questionnaire to the patient’s initial visit can also help validate the diagnosis in the minds of patients and also clinicians. We had patients in a rheumatology office practice complete this diagnostic form.
Methods: There are 19 pain areas listed. Patients checked a box next to the areas of pain during the last 7 days and replied to questions for the other symptoms- sleep (0-3), energy (0-3), cognition (0-3), and abdominal pain (0-1), headaches (0-1) and depression (0-1). A score of 12 and above is consistent with fibromyalgia.
Results: 60 patients with various rheumatic diseases, but excluding primary fibromyalgia, filled out the assessment form developed for the 2010 ACR diagnostic criteria. In those patients with an underlying inflammatory rheumatic disease diagnosis, without known fibromyalgia, 14 (23.3%) had a finding of 12 or more points using the fibromyalgia diagnostic screening form.
Conclusion: The fibromyalgia screening form developed in conjunction with the ACR 2010 criteria for fibromyalgia diagnosis can be quite helpful in determining the presence of concomitant fibromyalgia. 23.3% of a group of patients with inflammatory arthritis, lupus, and osteoarthritis also had fibromyalgia, according to the screening form results.
This form can be used to suggest the possibility of concomitant fibromyalgia in patients with other rheumatic diseases. Concomitant fibromyalgia and an inflammatory rheumatic disease may be a reason for the failure of biologic modifier and other therapy aimed at reducing pain and improving global well-being.
To cite this abstract in AMA style:Katz RS, Polyak JL. Fibromyalgia Screening Form in the Diagnosis of Concomitant Fibromyalgia [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/fibromyalgia-screening-form-in-the-diagnosis-of-concomitant-fibromyalgia-2/. Accessed September 24, 2021.
« Back to 2017 ACR/ARHP Annual Meeting
ACR Meeting Abstracts - https://acrabstracts.org/abstract/fibromyalgia-screening-form-in-the-diagnosis-of-concomitant-fibromyalgia-2/